BOSTON, Mass. — Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company developing precision medicines for autoimmune and inflammatory diseases, announced the appointment of Nia Tatsis, Ph.D., to its Board of Directors. Dr. Tatsis currently serves as Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals and brings more than two decades of experience in regulatory affairs, quality assurance, and clinical development.
“I am thrilled to welcome Nia to the board of Odyssey as we advance our RIPK2 scaffolding inhibitor and broader pipeline through clinical development,” said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. “Nia’s deep expertise spanning clinical development, regulatory, manufacturing, and commercialization will be invaluable as we continue on our mission of delivering transformative medicines to patients in need.”
Dr. Tatsis joined Vertex in 2017, where she oversees global regulatory and quality operations. Her prior leadership roles include senior regulatory positions at Sanofi, Stemnion, Pfizer, and Wyeth. She has also served on the board of Verve Therapeutics and is a member of the Leadership Council for the International Institute of New England. Dr. Tatsis earned her B.S. in Biology from Temple University and a Ph.D. in Cell and Molecular Biology from the University of Vermont, followed by postdoctoral research in immunology at Thomas Jefferson University.
“Odyssey has rapidly advanced a compelling pipeline of potentially transformative immunology medicines in just four years since its founding,” said Dr. Tatsis. “I look forward to working with Odyssey to advance its pipeline and bring multiple new medicines to the market in the coming years to improve the quality of life for patients living with serious immune diseases.”
